Management of adjuvant XXXX therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification.

@entity1 @entity137 @entity11730 @entity1910 @entity5 @entity294 @entity448 @entity1431 @entity1011
BACKGROUND: The aim of this study was to determine the optimal management of adjuvant @entity11730 therapy for @entity5 , encompassing the details of dose reduction and treatment schedule modification. METHODS: We retrospectively examined 97 @entity1 with @entity5 who received @entity11730 chemotherapy following gastrectomy between January 2003 and December 2007. @entity11730 (80 mg/m   per day) was orally administered twice daily for 4 weeks, followed by a 2-week rest. As a rule, treatment was continued for 1 year after gastrectomy. Dose reduction or treatment schedule modification was performed according to @entity137 profiles. RESULTS: Among the 97 @entity1 , 57 (59%) underwent dose reduction at least once and 39 (40%) received treatment schedule modification. Of the 57 @entity1 who required dose reduction, 45 (79%) underwent reduction within 3 months of the beginning of treatment. The most common reasons for dose reduction were @entity448 (47%), followed by @entity294 (32%), @entity1431 (24%), and @entity1910 (16%), with the reasons overlapping. Although the difference in the requirement for dose reduction was not significant, @entity1 with a low @entity1011 clearance level or those who underwent total gastrectomy had a greater tendency to require dose reduction. The duration of the @entity11730 treatment period was at least 3 months in 88% of the @entity1 , at least 6 months in 82%, and the planned 1-year period in 73% of the @entity1 . CONCLUSIONS: In most @entity1 , the planned 1-year adjuvant @entity11730 therapy for @entity5 could be completed by modifying the dose reduction and treatment schedule.
